Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

36-017 Anti-cleaved-Tau (Asp421) Antibody, clone C3

36-017
100 µL  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
H, M, RIP, WB, IHCMPurifiedMonoclonal Antibody
Description
Catalogue Number36-017
Brand Family Upstate
Trade Name
  • Upstate
DescriptionAnti-cleaved-Tau (Asp421) Antibody, clone C3
References
Product Information
FormatPurified
Presentation0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the addition of glycerol
Quality LevelMQ100
Applications
ApplicationAnti-cleaved-Tau (Asp421) Antibody, clone C3 is an antibody against cleaved-Tau (Asp421) for use in IP, WB, IH.
Key Applications
  • Immunoprecipitation
  • Western Blotting
  • Immunohistochemistry
Biological Information
ImmunogenSynthetic peptide corresponding to amino acids 412-421(CSSTGSIDMVD) of human Tau with a Cys at the N-terminal end
Cloneclone C3
HostMouse
Specificitycleaved-Tau
IsotypeIgG1
Species Reactivity
  • Human
  • Mouse
  • Rat
Antibody TypeMonoclonal Antibody
Entrez Gene Number
Entrez Gene SummaryThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
Gene Symbol
  • MAPT
  • MTBT2
  • MAPTL
  • PHF-tau
  • tau
  • DDPAC
  • FTDP-17
  • MGC138549
  • MSTD
  • TAU
  • FLJ31424
  • MTBT1
  • PPND
Purification MethodProtein A Purfied
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P10636 # Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
SIZE: 758 amino acids; 78878 Da
SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.
SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
DOMAIN: SwissProt: P10636 The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K- X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser- 622, Ser-641 and Ser-673 in several isoforms during mitosis. & Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. & Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
DISEASE: SwissProt: P10636 # In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). & Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. & Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia. & Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. & Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson- Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. & Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.
SIMILARITY: Contains 4 Tau/MAP repeats.
Molecular Weight50-70kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality Assuranceroutinely evaluated by immunoblot on Tau fusion protein cleaved by Caspase 3 (Catalog #14-264)
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions2 years at -20°C
Packaging Information
Material Size100 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
36-017 04053252275302

Documentation

Anti-cleaved-Tau (Asp421) Antibody, clone C3 SDS

Title

Safety Data Sheet (SDS) 

Anti-cleaved-Tau (Asp421) Antibody, clone C3 Certificates of Analysis

TitleLot Number
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) 2999828
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) 3013320
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) 2892926
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) 2935881
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) 3101531
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) 3046670
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) - 2145959 2145959
Anti-cleaved-Tau (Asp421), clone C3 (mouse monoclonal IgG1) - 2275557 2275557
Anti-cleaved-Tau (Asp421), clone C3 - 27027 27027
Anti-cleaved-Tau (Asp421), clone C3 - 3163499 3163499

References

Reference overviewPub Med ID
Modeling tau polymerization in vitro: a review and synthesis.
Gamblin, T Chris, et al.
Biochemistry, 42: 15009-17 (2003)  2003

Show Abstract
14690409 14690409
Argyrophilic grain disease is a sporadic 4-repeat tauopathy
Togo, Takashi, et al
J Neuropathol Exp Neurol, 61:547-56 (2002)  2002

12071638 12071638
The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons.
Utton, Michelle A, et al.
J. Neurosci., 22: 6394-400 (2002)  2002

Show Abstract
12151518 12151518

Newsletters / Publications

Title
Research Focus - Volume 2, 2013

Related Products & Applications

Product Families

Categories

Life Science Research > Antibodies and Assays > Primary Antibodies